Implementing Low-Barrier HCV Treatment in a Jail Setting

Официальное название

MINMON-J: An Effectiveness Implementation Pilot Study Evaluating a Low-barrier Hepatitis C Treatment Model in a Jail Setting

Обзор

The goal of this clinical trial is to learn whether a low-barrier treatment program can help people with hepatitis C virus (HCV) who are in jail start and complete treatment more easily. This study focuses on adults at the Rhode Island Department of Corrections who have active HCV and are awaiting trial. The study asks: * Can a simplified, low-barrier HCV treatment program work in a jail setting? * Do participants finish treatment and get cured using this approach? All participants will receive a 12-week course of the HCV medication sofosbuvir/velpatasvir (Epclusa). If they are released before completing treatment, they will take the remaining doses with them. Community Health Workers (CHWs) will help support participants after release, including reminding them to take medications and helping them get follow-up lab work. Researchers will measure: * Whether participants are cured of HCV * Whether the treatment approach is easy to use (feasible), acceptable, and followed correctly (fidelity) * Whether the program could be used in other jails or expanded in the future This study may help bring HCV treatment to more people in jail, reduce community spread of the virus, and support national goals to eliminate HCV.

Подробное описание

This is a hybrid effectiveness-implementation pilot study testing a simplified model of hepatitis C virus (HCV) treatment called MINMON-J, based on the successful "minimal monitoring" approach used in community settings. The study takes place at the Rhode Island Department of Corrections (RIDOC), a statewide unified jail and prison system. The goal is to assess whether low-barrier HCV treatment can be feasible, acceptable, and effective when started in jail, especially for individuals who inject drugs.

Participants will receive a full 12-week course of sofosbuvir/velpatasvir (Epclusa) with no lab monitoring required during treatment. Those released before completing treatment will be given take-home medication and supported by Community Health Workers (CHWs) post-release. CHWs will check in with participants, support medication adherence, and help coordinate follow-up testing.

The study will enroll 40 adults with active HCV who are awaiting trial and meet other medical and safety criteria. Implementation outcomes will be assessed using the PRISM/RE-AIM framework. These include:

Feasibility: Can the treatment be delivered as planned in the jail setting? Acceptability: Do participants and providers find the program acceptable? Fidelity: Do participants take the medication as prescribed? Effectiveness: Are participants cured of HCV (measured by SVR12)? Maintenance: Do participants remain engaged in care or avoid reinfection 6 months later?

Additional data will include participant demographics, adherence rates, and program costs (via the COINS framework). Participants and staff will also take part in qualitative interviews to understand their experience and identify ways to improve implementation. Results will inform a future larger trial and contribute to efforts to scale up HCV treatment in carceral settings as part of national HCV elimination efforts.

Вмешательства

• Препарат Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]
  Individuals will receive a full course (i.e., 84 tablets) of Sofosbuvir / Velpatasvir 400/100mg tablets.
• Другое Community Health Worker
  Participants will receive support from a Community Health Worker which may include assistance with basic needs (transportation, housing, employment, vital documents, insurance re-activation) as well as medication adherence, patient navigation, and peer recovery support.

Первичные конечные точки

• HCV Cure Rate [Срок оценки: Between 12 and 24 weeks after completion of HCV treatment]

Вторичные конечные точки (4)

• Implementation: Feasibility of Implementation Measure [Срок оценки: Between 4 to 12 weeks post-implementation]
• Fidelity: In-facility Treatment Adherence [Срок оценки: From enrollment to the end of treatment at 12 weeks]
• Fidelity: Community Treatment Adherence [Срок оценки: From enrollment to the end of treatment at 12 weeks]
• Implementation: Acceptability of Implementation Measure [Срок оценки: Between 4 to 12 weeks post-implementation]

Критерии участия

Критерии включения

• Incarcerated individual at RIDOC
• Age ≥ 18 years
• Awaiting trial (i.e., not sentenced)
• English speaking
• Diagnosis of active HCV (HCV RNA >1000 IU/mL within 90 days prior to study entry)
• Treatment-naïve for current HCV infection
• No cirrhosis (FIB-4 Score <3.25 within 90 days prior to study entry)
• Self-report of injection drug use
• Ability and willingness to be contacted after jail release
• Verbal commitment to continue medication after discharge
• Desire to receive Sofosbuvir/Velpatasvir (Epclusa)

Критерии исключения

• Cirrhosis (FIB-4 Score >3.25 within 90 days prior to study entry and/or clinical signs of cirrhosis)
• Positive for Hepatitis B surface antigen
• Actively pregnant or breastfeeding
• Known allergy/sensitivity to study drug components
• Acute or serious illness requiring hospitalization at enrollment
• Documented severe persistent mental illness (SPMI) by RIDOC
• Any clinical history of hepatic decompensation (e.g., ascites, SBP, HE, HRS, variceal bleeding)
• HIV-positive with active or acute AIDS-defining opportunistic infection within 90 days

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

США · 1 центр

• Rhode Island Department of Corrections — Cranston

Публикации

• Berk J, Fu ES, Murphy M, Akiyama MJ, Sulkowski M, Rich JD, Frank HE. MINMON-J: a hybrid implementation pilot study evaluating a low-barrier hepatitis C treatment model in a jail setting. BMJ Open. 2025 Sep 30;15(9):e104839. doi: 10.1136/bmjopen-2025-104839. PMID 41027703

Идентификаторы

NCT: NCT06953479 · IRB 2240400 · R34DA061732

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗